Measuring a Sugar Marker in Saliva for People With and Without Type 2 Diabetes
Studies a saliva test for 1,5-anhydroglucitol in adults with and without type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Clinical Evaluation of Salivary 1,5-Anhydroglucitol in Diabetes
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07781683, who can take part
Where in China
- Shanghai Sixth People's HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 6th People's Hospital
- Trial code
- NCT07781683
- Record updated
- 25 August 2026
- Original description
The goal of this observational study is to evaluate the clinical value of salivary 1,5-anhydroglucitol (1,5-AG) and assess a novel noninvasive detection approach in individuals with and without type 2 diabetes. Additionally, the study will examine the relationships of salivary 1,5-AG with serum 1,5-AG and continuous glucose monitoring (CGM) measures of short-term glycemic control and fluctuations.Read full original descriptionShow less
Development and Application of a Novel Noninvasive Salivary 1,5-Anhydroglucitol Detection Technology in Diabetes Management
The goal of this observational study is to evaluate the clinical value of salivary 1,5-anhydroglucitol (1,5-AG) and assess a novel noninvasive detection approach in individuals with and without type 2 diabetes. Additionally, the study will examine the relationships of salivary 1,5-AG with serum 1,5-AG and continuous glucose monitoring (CGM) measures of short-term glycemic control and fluctuations.
Inclusion: Aged between 18 and 80 years; Individuals without a history of diabetes, or patients with type 2 diabetes mellitus.
Exclusion: History of systemic glucocorticoid treatment within the previous 6 weeks; Presence of acute infection; Presence of severe oral conditions that may affect saliva collection or measurement; History of alcohol abuse or psychiatric disorders, including depression; Current treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors; Presence of severe hepatic or renal dysfunction.